LAMEA Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023

List of Tables

The Latin America, Middle East and Africa Guillain-Barre Syndrome Market would witness market growth of 6.2% CAGR during the forecast period (2023-2030).

The Brazil market dominated the LAMEA Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $15,320.9 Thousands by 2030. The Argentina market is registering a CAGR of 7.1% during (2023 - 2030). Additionally, The UAE market would showcase a CAGR of 5.9% during (2023 - 2030).

cerebrospinal fluid (CSF) analysis lumbar puncture is performed to obtain CSF samples for analysis, including cell counts, protein levels, and the presence of inflammatory markers such as elevated protein levels without an increase in white blood cells, indicative of albumin cytologic dissociation, a hallmark of GBS.

Additionally, magnetic resonance imaging (MRI) of the spine and nerve roots may reveal characteristic findings such as nerve root enhancement, nerve enlargement, or spinal cord abnormalities, supporting the diagnosis of GBS and ruling out other neurological conditions.

The World Health Organization (WHO) reports that 130 suspected cases of GBS were reported in Peru between June 10, 2023, and July 15, 2023. 44 of these cases have been verified. The number of instances observed has increased more than anticipated. Additionally, 231 probable GBS cases were reported in Peru between epidemiological weeks 1 and 28 (until July 15, 2023). Thus, the rising aging population and increasing healthcare expenditure in the LAMEA region propel the market's growth.

Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

List of Key Companies Profiled

F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
PTC, Inc.
AstraZeneca PLC
Novartis AG
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Bayer AG
Merck & Co., Inc.
Bristol Myers Squibb Company

LAMEA Guillain-Barre Syndrome Market Report Segmentation

By Therapeutics

Intravenous Immunoglobulin
Plasma Exchange
Others

By Route Of Administration

Parenteral
Oral

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

By Country

Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA

Chapter 1.Market Scope & Methodology

1.1Market Definition
1.2Objectives
1.3Market Scope
1.4Segmentation
- 1.4.1LAMEA Guillain-Barre Syndrome Market, by Therapeutics
- 1.4.2LAMEA Guillain-Barre Syndrome Market, by Route Of Administration
- 1.4.3LAMEA Guillain-Barre Syndrome Market, by Distribution Channel
- 1.4.4LAMEA Guillain-Barre Syndrome Market, by Country
1.5Methodology for the research

Chapter 2.Market at a Glance

2.1Key Highlights

Chapter 3.Market Overview

3.1Introduction
- 3.1.1Overview
  - 3.1.1.1Market Composition and Scenario
3.2Key Factors Impacting the Market
- 3.2.1Market Drivers
- 3.2.2Market Restraints
- 3.2.3Market Opportunities
- 3.2.4Market Challenges
3.3Porter Five Forces Analysis

Chapter 4.LAMEA Guillain-Barre Syndrome Market by Therapeutics

4.1LAMEA Intravenous Immunoglobulin Market by Country
4.2LAMEA Plasma Exchange Market by Country
4.3LAMEA Others Market by Country

Chapter 5.LAMEA Guillain-Barre Syndrome Market by Route Of Administration

5.1LAMEA Parenteral Market by Country
5.2LAMEA Oral Market by Country

Chapter 6.LAMEA Guillain-Barre Syndrome Market by Distribution Channel

6.1LAMEA Hospital Pharmacies Market by Country
6.2LAMEA Retail Pharmacies Market by Country
6.3LAMEA Others Market by Country

Chapter 7.LAMEA Guillain-Barre Syndrome Market by Country

7.1Brazil Guillain-Barre Syndrome Market
- 7.1.1Brazil Guillain-Barre Syndrome Market by Therapeutics
- 7.1.2Brazil Guillain-Barre Syndrome Market by Route Of Administration
- 7.1.3Brazil Guillain-Barre Syndrome Market by Distribution Channel
7.2Argentina Guillain-Barre Syndrome Market
- 7.2.1Argentina Guillain-Barre Syndrome Market by Therapeutics
- 7.2.2Argentina Guillain-Barre Syndrome Market by Route Of Administration
- 7.2.3Argentina Guillain-Barre Syndrome Market by Distribution Channel
7.3UAE Guillain-Barre Syndrome Market
- 7.3.1UAE Guillain-Barre Syndrome Market by Therapeutics
- 7.3.2UAE Guillain-Barre Syndrome Market by Route Of Administration
- 7.3.3UAE Guillain-Barre Syndrome Market by Distribution Channel
7.4Saudi Arabia Guillain-Barre Syndrome Market
- 7.4.1Saudi Arabia Guillain-Barre Syndrome Market by Therapeutics
- 7.4.2Saudi Arabia Guillain-Barre Syndrome Market by Route Of Administration
- 7.4.3Saudi Arabia Guillain-Barre Syndrome Market by Distribution Channel
7.5South Africa Guillain-Barre Syndrome Market
- 7.5.1South Africa Guillain-Barre Syndrome Market by Therapeutics
- 7.5.2South Africa Guillain-Barre Syndrome Market by Route Of Administration
- 7.5.3South Africa Guillain-Barre Syndrome Market by Distribution Channel
7.6Nigeria Guillain-Barre Syndrome Market
- 7.6.1Nigeria Guillain-Barre Syndrome Market by Therapeutics
- 7.6.2Nigeria Guillain-Barre Syndrome Market by Route Of Administration
- 7.6.3Nigeria Guillain-Barre Syndrome Market by Distribution Channel
7.7Rest of LAMEA Guillain-Barre Syndrome Market
- 7.7.1Rest of LAMEA Guillain-Barre Syndrome Market by Therapeutics
- 7.7.2Rest of LAMEA Guillain-Barre Syndrome Market by Route Of Administration
- 7.7.3Rest of LAMEA Guillain-Barre Syndrome Market by Distribution Channel

Chapter 8.Company Profiles

8.1F. Hoffmann-La Roche Ltd.
- 8.1.1Company Overview
- 8.1.2Financial Analysis
- 8.1.3Segmental and Regional Analysis
- 8.1.4Research & Development Expense
- 8.1.5SWOT Analysis
8.2Pfizer, Inc.
- 8.2.1Company Overview
- 8.2.2Financial Analysis
- 8.2.3Regional & Segmental Analysis
- 8.2.4Research & Development Expense
- 8.2.5SWOT Analysis
8.3PTC, Inc.
- 8.3.1Company Overview
- 8.3.2Financial Analysis
- 8.3.3Segmental and Regional Analysis
- 8.3.4Research & Development Expenses
- 8.3.5SWOT Analysis
8.4AstraZeneca PLC
- 8.4.1Company Overview
- 8.4.2Financial Analysis
- 8.4.3Regional Analysis
- 8.4.4Research & Development Expenses
- 8.4.5SWOT Analysis
8.5Novartis AG
- 8.5.1Company Overview
- 8.5.2Financial Analysis
- 8.5.3Segmental and Regional Analysis
- 8.5.4Research & Development Expense
- 8.5.5Recent strategies and developments:
  - 8.5.5.1Partnerships, Collaborations, and Agreements:
- 8.5.6SWOT Analysis
8.6Novo Nordisk A/S
- 8.6.1Company Overview
- 8.6.2Financial Analysis
- 8.6.3Segmental and Regional Analysis
- 8.6.4Research & Development Expenses
- 8.6.5SWOT Analysis
8.7Takeda Pharmaceutical Company Limited
- 8.7.1Company Overview
- 8.7.2Financial Analysis
- 8.7.3Regional Analysis
- 8.7.4Research & Development Expense
- 8.7.5SWOT Analysis
8.8Bayer AG
- 8.8.1Company Overview
- 8.8.2Financial Analysis
- 8.8.3Segmental and Regional Analysis
- 8.8.4Research & Development Expense
- 8.8.5SWOT Analysis
8.9Merck & Co., Inc.
- 8.9.1Company Overview
- 8.9.2Financial Analysis
- 8.9.3Segmental and Regional Analysis
- 8.9.4Research & Development Expenses
- 8.9.5Recent strategies and developments:
  - 8.9.5.1Partnerships, Collaborations, and Agreements:
- 8.9.6SWOT Analysis
8.10.Bristol Myers Squibb Company
- 8.10.1Company Overview
- 8.10.2Financial Analysis
- 8.10.3Regional Analysis
- 8.10.4Research & Development Expenses
- 8.10.5SWOT Analysis

LIST OF TABLES

TABLE 1LAMEA Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 2LAMEA Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 3LAMEA Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 4LAMEA Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 5LAMEA Intravenous Immunoglobulin Market by Country, 2019 - 2022, USD Thousands
TABLE 6LAMEA Intravenous Immunoglobulin Market by Country, 2023 - 2030, USD Thousands
TABLE 7LAMEA Plasma Exchange Market by Country, 2019 - 2022, USD Thousands
TABLE 8LAMEA Plasma Exchange Market by Country, 2023 - 2030, USD Thousands
TABLE 9LAMEA Others Market by Country, 2019 - 2022, USD Thousands
TABLE 10LAMEA Others Market by Country, 2023 - 2030, USD Thousands
TABLE 11LAMEA Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 12LAMEA Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 13LAMEA Parenteral Market by Country, 2019 - 2022, USD Thousands
TABLE 14LAMEA Parenteral Market by Country, 2023 - 2030, USD Thousands
TABLE 15LAMEA Oral Market by Country, 2019 - 2022, USD Thousands
TABLE 16LAMEA Oral Market by Country, 2023 - 2030, USD Thousands
TABLE 17LAMEA Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 18LAMEA Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 19LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Thousands
TABLE 20LAMEA Hospital Pharmacies Market by Country, 2023 - 2030, USD Thousands
TABLE 21LAMEA Retail Pharmacies Market by Country, 2019 - 2022, USD Thousands
TABLE 22LAMEA Retail Pharmacies Market by Country, 2023 - 2030, USD Thousands
TABLE 23LAMEA Others Market by Country, 2019 - 2022, USD Thousands
TABLE 24LAMEA Others Market by Country, 2023 - 2030, USD Thousands
TABLE 25LAMEA Guillain-Barre Syndrome Market by Country, 2019 - 2022, USD Thousands
TABLE 26LAMEA Guillain-Barre Syndrome Market by Country, 2023 - 2030, USD Thousands
TABLE 27Brazil Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 28Brazil Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 29Brazil Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 30Brazil Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 31Brazil Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 32Brazil Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 33Brazil Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 34Brazil Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 35Argentina Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 36Argentina Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 37Argentina Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 38Argentina Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 39Argentina Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 40Argentina Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 41Argentina Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 42Argentina Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 43UAE Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 44UAE Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 45UAE Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 46UAE Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 47UAE Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 48UAE Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 49UAE Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 50UAE Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 51Saudi Arabia Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 52Saudi Arabia Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 53Saudi Arabia Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 54Saudi Arabia Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 55Saudi Arabia Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 56Saudi Arabia Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 57Saudi Arabia Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 58Saudi Arabia Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 59South Africa Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 60South Africa Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 61South Africa Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 62South Africa Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 63South Africa Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 64South Africa Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 65South Africa Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 66South Africa Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 67Nigeria Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 68Nigeria Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 69Nigeria Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 70Nigeria Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 71Nigeria Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 72Nigeria Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 73Nigeria Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 74Nigeria Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 75Rest of LAMEA Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 76Rest of LAMEA Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 77Rest of LAMEA Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 78Rest of LAMEA Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 79Rest of LAMEA Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 80Rest of LAMEA Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 81Rest of LAMEA Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 82Rest of LAMEA Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 83Key Information - F. Hoffmann-La Roche Ltd.
TABLE 84Key Information - Pfizer, Inc.
TABLE 85key Information - PTC, Inc.
TABLE 86KEY INFORMATION - AstraZeneca PLC
TABLE 87Key Information - Novartis AG
TABLE 88Key Information - Novo Nordisk A/S
TABLE 89Key Information - Takeda Pharmaceutical Company Limited
TABLE 90Key Information - Bayer AG
TABLE 91Key Information - Merck & Co., Inc.
TABLE 92Key Information - Bristol Myers Squibb Company

LAMEA Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Description

Table of Contents